About: http://data.cimple.eu/news-article/7039689c0da80fd363e75a4110d29ac7b5eece05698b5f01e7bb0df4     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Britain's Oxford University said on Friday its researchers behind the joint AstraZeneca Covid-19 vaccine had found it to be effective against the UK virus variant now dominant across the country. The university, which developed the jab with the British-Swedish pharmaceutical firm, said an ongoing assessment of its effectiveness showed that it has "similar efficacy" to other coronavirus strains. "Data from our trials... in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus, but also protects against the novel variant," said Andrew Pollard, co-chief investigator on the Oxford vaccine trial. The analysis, which relied on samples taken between October and mid-January, also indicated the jab reduces "duration of shedding and viral load", which may translate into reduced virus transmission, the university said. The preliminary findings, which still need to be peer reviewed, are the first to report on the efficacy of the Oxford-AstraZeneca vaccine against new variants, it noted. The more contagious British virus variant, which first emerged in southeast England in late September, has since become the most common strain detected in new UK infections, and spread to scores of other countries. However, it is less clear how well the vaccines developed so far will work against several other variants that have emerged around the world, in particular a strain from South Africa that is causing concern. Oxford said vaccine researchers are looking at ways to modify existing inoculations "quickly and simply" to protect against new variants. "We have always expected that as the pandemic continues, new variants will begin to become dominant amongst the viruses that are circulating and that eventually a new version of the vaccine... would be required," said Sarah Gilbert, co-chief investigator of the Oxford trial. "We are working with AstraZeneca to optimise the pipeline required for a strain change should one become necessary." jj/phz/har
schema:headline
  • AstraZeneca vaccine effective against UK variant: Oxford University
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software